2025-10-04 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM) based on the information you provided. I'll present the analysis in English, starting with key numbers and then providing context and insights.

## TEM Stock Analysis

**Ticker:** TEM
**Company:** Unknown Company (Precision oncology company using AI and data to personalize healthcare.)

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 46.86%
*   **VOO Cumulative Return:** 27.73%
*   **Absolute Divergence (Current):** 15.6
*   **Relative Divergence:** 48.9

**Analysis:** TEM has significantly outperformed the S&P 500 since its IPO. The relative divergence of 48.9 indicates TEM's outperformance is positioned in the middle range of its historical divergence from VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2023-2025 | 47.0% | 70.1% | 20.0% | 0.3  | 15.9   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** A high CAGR of 47.0% suggests strong growth potential.
*   **MDD (Maximum Drawdown):** A significant MDD of 70.1% indicates high volatility and risk.
*   **Alpha:** A positive alpha of 20.0% shows TEM's ability to generate returns above the market, even when considering market risk.
*   **Beta:** A low beta of 0.3 suggests that TEM's price is not very sensitive to market movements, which could be seen as a positive during market downturns.
*   **Cap(B):** The market capitalization of $15.9 billion suggests a mid-cap company.

### 2. Recent Price Action

*   **Current Price:** $91.66
*   **Previous Close:** $89.30
*   **Change:** +$2.64
*   **5-Day Moving Average:** $85.80
*   **20-Day Moving Average:** $83.97
*   **60-Day Moving Average:** $72.24

**Analysis:** The stock is trading above all its short-term and medium-term moving averages, indicating a bullish trend. The recent price increase of $2.64 suggests positive momentum.

### 3. Indicators and Signals

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 61.06
*   **PPO (Percentage Price Oscillator):** 0.16
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash (11 shares - Very Safe - MRI:0.90)"
*   **Recent Relative Divergence Change (20-day):** +12.6 (Short-term Increase)
*   **Expected Return:** NaN

**Analysis:**

*   The MRI suggests that the stock is currently in a "High Investment Recommended" range.
*   The RSI of 61.06 is nearing overbought territory (typically above 70).
*   The PPO is positive, supporting the bullish trend.
*   The Hybrid Signal recommends a full investment, indicating confidence in the stock's potential.
*   The recent increase in relative divergence suggests that TEM is outperforming the S&P 500 in the short term.
*   The "NaN" expected return might indicate missing or unreliable data for long-term forecasts.
*   **The price change of $2.64 from the previous close indicates a notable positive change, suggesting recent positive momentum for the stock.**

### 4. Recent News & Significant Events

*   **FDA Clearances:** Multiple news items highlight FDA clearances for Tempus AI's products, indicating regulatory approval and potential for growth.
*   **Analyst Coverage:** Articles discuss Tempus AI's valuation and compare it to competitors, suggesting increasing investor interest.
*   **EHR Integration:** News of improved EHR integration suggests expanding market reach and accessibility.

**Analysis:** The news flow is overwhelmingly positive, driven by FDA clearances, analyst attention, and product improvements. This positive sentiment likely contributes to the stock's recent performance.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (2.15 on a 1-5 scale)
*   **Target Price (Avg):** $77.55
*   **Target Price (High):** $100.00
*   **Target Price (Low):** $60.00

**Analysis:** Analyst consensus is positive with a "Buy" rating. The average target price is below the current price, suggesting limited upside potential based on analyst estimates. However, the high target price indicates some analysts see significant upside.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
|------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:** TEM is not yet profitable, as indicated by negative EPS values. However, the company has consistently beaten EPS estimates in recent quarters, suggesting positive operational momentum.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $0.31B  | -13.84%  |
| 2025-03-31 | $0.33B  | -20.86%  |
| 2024-12-31 | $0.06B  | -23.10%  |
| 2024-09-30 | $0.05B  | -141.16% |
| 2024-06-30 | $0.10B  | -562.04% |

**Analysis:**

*   **Revenue:** Revenue is growing steadily, indicating increasing adoption of Tempus AI's products and services.
*   **Profit Margin:** High and increasing profit margins suggest strong pricing power and efficient operations.
*   **Equity:** Equity has fluctuated, but is generally trending upwards.
*   **ROE (Return on Equity):** Negative ROE values reflect the company's current lack of profitability.

### 7. Overall Assessment

**Summary:**

TEM is a high-growth, high-risk stock in the precision oncology space. It has significantly outperformed the S&P 500 since its IPO, driven by positive news flow (FDA clearances), increasing revenue, and high profit margins. Analyst consensus is positive, although the average target price suggests limited near-term upside.

**Key Considerations:**

*   **Valuation:** The stock's valuation appears high, given its current lack of profitability.
*   **Risk Tolerance:** The high MDD and volatility make this stock suitable for investors with a high risk tolerance.
*   **Growth Potential:** The company's strong revenue growth and innovative technology suggest significant long-term growth potential.
*   **Market Sentiment:** Positive news flow and analyst coverage are currently supporting the stock's price.

**Recommendation:**

TEM appears to be a promising investment for growth-oriented investors who are comfortable with high risk. However, investors should carefully consider the stock's valuation and monitor its financial performance closely. The recent pullback from record highs mentioned in the news suggests a potential entry point, but further due diligence is recommended. It would be wise to keep tabs on those FDA approvals and any competitors.
